Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine

Information

  • Patent Grant
  • 9371310
  • Patent Number
    9,371,310
  • Date Filed
    Tuesday, March 24, 2015
    9 years ago
  • Date Issued
    Tuesday, June 21, 2016
    8 years ago
Abstract
3-(3-Chloro-1H-pyrazol-1-yl)pyridine is prepared by coupling 3-bromopyridine with commercially available 3-aminopyrazole, purifying the 3-(3-amino-1H-pyrazol-1-yl)pyridine by crystallization, and converting the amino group to a chloro group by a Sandmeyer reaction.
Description
BACKGROUND

The present invention concerns an improved process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine.


US 20130288893(A1) describes, inter alia, certain (3-halo-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amides and carbamates and their use as pesticides. The route to prepare such compounds involved the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine by the direct coupling of 3-bromopyridine with 3-chloropyrazole. The 3-chloropyrazole was prepared by a) treating 1H-pyrazole with 2-dimethylsulfamoyl chloride and sodium hydride to provide N,N-dimethyl-1H-pyrazole-1-sulfonamide, b) treating the N,N-dimethyl-1H-pyrazole-1-sulfonamide with perchloroethane and n-butyl lithium to provide 3-chloro-N,N-dimethyl-1H-pyrazole-1-sulfonamide, and c) removing the N,N-dimethylsulfonamide from 3-chloro-N,N-dimethyl-1H-pyrazole-1-sulfonamide with trifluoroacetic acid to give the 3-chloropyrazole.


The disclosed process produces low yields, relies on a starting material that is difficult to prepare (3-chloropyrazole) and provides a product that is difficult to isolate in a pure form. It would be desirable to have a process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) that avoids these problems.


SUMMARY

The present invention provides such an alternative by coupling 3-bromopyridine with commercially available 3-aminopyrazole, purifying the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) by crystallization, and converting the amino group to a chloro group by a Sandmeyer reaction. Thus, the present invention concerns a process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b),




embedded image



which comprises


a) treating 3-bromopyridine




embedded image



with 3-aminopyrazole




embedded image



in a water-miscible polar aprotic organic solvent at a temperature of about 75° C. to about 155° C. in the presence of a catalytic amount of copper(I) chloride and a base to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a)




embedded image


b) crystallizing the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) from water;


c) treating the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) in aqueous hydrochloric acid with sodium nitrite at a temperature of about 0° C. to about 25° C. to provide the diazonium salt (8b)




embedded image



and


d) treating the diazonium salt (8b) with copper chloride at a temperature of about 0° C. to about 25° C.







DETAILED DESCRIPTION

The present invention provides an improved process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) by coupling 3-bromopyridine with commercially available 3-aminopyrazole, purifying the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) by crystallization, and converting the amino group to a chloro group by a Sandmeyer reaction.


In the first step, 3-bromopyridine is coupled with 3-aminopyrazole in a water-miscible polar aprotic organic solvent at a temperature of about 75° C. to about 155° C. in the presence of a catalytic amount of copper chloride and a base to provide 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a). While stoichiometric amounts of 3-bromopyridine and 3-aminopyrazole are required, it is often convenient to use an excess of 3-aminopyrazole. An excess from about 10 mole percent to about 50 mole percent 3-aminopyrazole is preferred. The coupling is run in the presence of about 5 mole percent to about 50 mole percent copper chloride, preferably from about 15 mole percent to about 30 mole percent copper chloride. The copper chloride may be either copper(I) chloride or copper(II) chloride. The coupling is also run in the presence of a base. While stoichiometric amounts of 3-bromopyridine and base are required, it is often convenient to use about a 1.5 fold to about a 2 fold excess of base. Alkali metal carbonates are preferred bases. The coupling is performed in a water-miscible polar aprotic organic solvent. Polar aprotic organic solvents that are soluble in water include nitriles such as acetonitrile, sulfoxides such as dimethyl sulfoxide, and amides such as N-methylpyrrolidinone, N,N-dimethylformamide, and N,N-dimethylacetamide. N,N-Dimethylformamide is particularly preferred.


In a typical reaction, copper(I) chloride, 3-aminopyrazole, potassium carbonate and N,N-dimethylformamide are introduced into a reaction vessel under a nitrogen atmosphere and 3-bromopyridine is gradually added. The mixture is heated at about 110° C. until most of the 3-bromopyridine has reacted. The mixture is allowed to cool and most of the solvent is removed under reduced pressure. The crude 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) is conveniently isolated and purified by crystallization from water.


The purified 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) is then converted to the desired 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) by treatment in aqueous hydrochloric acid with sodium nitrite at a temperature of about 0° C. to about 25° C. to provide a diazonium salt followed by treatment of the diazonium salt with copper chloride at a temperature of about 0° C. to about 25° C. While stoichiometric amounts of reagents are required, it is often convenient to use an excesses of reagents with respect to the 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a). Thus, aqueous hydrochloric acid is used in large excess as the reaction medium. Sodium nitrite is used in about a 1.5 fold to about a 2 fold excess. Copper chloride is used in about 5 mole percent to about 50 mole percent excess, preferably from about 15 mole percent to about 30 mole percent excess. The copper chloride may be either copper(I) chloride, copper(II) chloride or copper powder. To suppress foaming during the reaction a water-immiscible organic solvent such as toluene or chloroform can be added during the treatment of the diazonium salt with copper chloride.


In a typical reaction, a mixture of 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a) and aqueous hydrochloric acid are mixed and cooled to about 0° C. An aqueous solution of sodium nitrite is slowly added maintaining the temperature below about 5° C. The suspension is stirred at about 0° C. for about 2 hours. In a separate vessel, a mixture of copper(I) chloride and toluene are cooled to about 0° C. and the chilled suspension of diazonium salt is added at a rate maintaining the temperature below about 5° C. The mixture is allowed to warm to about ambient temperature. After completion of the reaction, the mixture is treated with aqueous sodium hydroxide to adjust the pH to about 8 to about 10. The resulting solution is extracted with a water-immiscible organic solvent. After removal of the solvent, the 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b) can be used directly in the next step, or further purified by standard techniques such as flash column chromatography or crystallization.


The following examples are presented to illustrate the invention.


EXAMPLES
1. Preparation of 3-(3-amino-1H-pyrazol-1-yl)pyridine (8a)



embedded image


A 4-neck round bottomed flask (500 mL) was charged with copper(I) chloride (2.51 g, 25.3 mmol), 1H-pyrazol-3-amine (15.8 g, 190 mmol), potassium carbonate (35.0 g, 253 mmol), and N,N-dimethylformamide (100 mL). The mixture was stirred under nitrogen for 10 minutes and 3-bromopyridine (12.2 mL, 127 mmol) was added. The mixture was heated at 110° C. for 18 hours, at which point HPLC analysis indicated that ˜15.5% 3-bromopyridine remained. The reaction was allowed to cool to 20° C. and concentrated to give a brown residue. Water (200 mL) was added and the resulting suspension was stirred at 20° C. for 2 hours and filtered. The solid was rinsed with water (2×50 mL) and dried to afford a pale green solid. The solid was suspended in water (200 mL) and the resulting suspension was heated at 90° C. for 2 hours and was filtered hot through a Celite® pad. The pad was rinsed with hot water (50 mL). The combined filtrates were allowed to cool to 20° C. to afford a yellow suspension, which was stirred at 20° C. for 2 hours and filtered. The solid was rinsed with water (2×50 mL) and air dried to afford the desired product as a light yellow crystalline solid (11.6 g, 57%): mp 169-172° C.; 1H NMR (400 MHz, DMSO-d6) δ 9.07-8.82 (m, 1H), 8.33 (dd, J=4.6, 1.5 Hz, 1H), 8.24 (d, J=2.6 Hz, 1H), 8.00 (ddd, J=8.4, 2.7, 1.4 Hz, 1H), 7.42 (ddd, J=8.5, 4.6, 0.8 Hz, 1H), 5.80 (d, J=2.6 Hz, 1H), 5.21 (s, 2H); 13C NMR (101 MHz, DMSO-d6) δ 157.67, 144.68, 138.00, 136.22, 128.30, 123.95, 123.17, 97.08; ESIMS m/z 161 ([M+H+]).


2. Preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b)



embedded image


To a 3-neck round bottomed flask (100 mL) was charged 3-(3-amino-1H-pyrazol-1-yl)pyridine (0.500 g, 3.12 mmol) and hydrochloric acid (37 wt %, 3 mL). The mixture was cooled to 0° C. and a solution of sodium nitrite (0.431 g, 6.24 mmol) in water (3 mL) was added in portions at <5° C. The resulting yellow suspension was stirred at 0° C. for 2 hours. To a separate 3-neck round bottomed flask (100 mL) was charged copper(I) chloride (0.371 g, 3.75 mmol) and toluene (3 mL). It was cooled to 0° C. and the yellow suspension was added in portions at <5° C. The resulting mixture was allowed to warm to 20° C. and stirred for 18 hours. It was basified with 50% sodium hydroxide to pH 10 and extracted with ethyl acetate (2×20 mL). The organic layers were concentrated to dryness and the residue was purified by flash column chromatography using 0-10% ethyl acetate/hexanes as eluent. The fractions containing the desired product were concentrated to give the title compound as a white solid (0.340 g, 61%): mp 104-106° C.; 1H NMR (400 MHz, CDCl3) δ 8.93 (d, J=27 Hz, 1H), 8.57 (dd, J=4.8, 1.4 Hz, 1H), 8.02 (ddd, J=8.3, 2.7, 1.5 Hz, 1H), 7.91 (d, J=2.6 Hz, 1H), 7.47-7.34 (M, 1H), 6.45 (d, J=2.6 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 148.01, 142.72, 140.12, 135.99, 128.64, 126.41, 124.01, 108.08; EIMS m/z 179 ([M]+).

Claims
  • 1. A process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b)
  • 2. The process of claim 1, wherein the water-miscible polar aprotic organic solvent is acetonitrile, dimethyl sulfoxide, N-methylpyrrolidinone, N,N-dimethylformamide or N,N-dimethylacetamide.
  • 3. The process of claim 2, wherein the water-miscible polar aprotic organic solvent is N,N-dimethylacetamide.
  • 4. The process of claim 1, wherein a water immiscible organic solvent is added in step d) to suppress foaming.
  • 5. The process of claim 1, wherein the copper chloride is copper (I) chloride.
  • 6. The process of claim 1, wherein the copper chloride is copper (II) chloride.
  • 7. The process of claim 1, wherein the copper chloride in step (d) is in an amount of from about 15 mole percent to 30 mole percent.
  • 8. The process of claim 4, wherein the water immiscible organic solvent is toluene or chloroform.
  • 9. A process for preparing 3-(3-chloro-1H-pyrazol-1-yl)pyridine (5b)
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/517,357 filed on Oct. 17, 2014, which claims the benefit of the following U.S. Provisional Patent Application Ser. No. 62/031,557 filed Jul. 31, 2014, the entire disclosures of which are hereby expressly incorporated by reference in this Application.

US Referenced Citations (90)
Number Name Date Kind
3597341 Oswald Aug 1971 A
4080457 Harrison et al. Mar 1978 A
4260765 Harrison et al. Apr 1981 A
4407803 Haviv et al. Oct 1983 A
4536506 Marcoux et al. Aug 1985 A
4824953 Bronn Apr 1989 A
5220028 Iwasawa et al. Jun 1993 A
5625074 Daum et al. Apr 1997 A
5631380 Haas et al. May 1997 A
5652372 Muller et al. Jul 1997 A
5693657 Lee et al. Dec 1997 A
5750718 Muller et al. May 1998 A
5817677 Linz et al. Oct 1998 A
5854264 Anthony et al. Dec 1998 A
5854265 Anthony et al. Dec 1998 A
5869681 Muller et al. Feb 1999 A
6040331 Yamamoto et al. Mar 2000 A
6218418 Pevarello et al. Apr 2001 B1
6506747 Betageri et al. Jan 2003 B1
6548525 Galemmo, Jr. et al. Apr 2003 B2
6720427 Sanner et al. Apr 2004 B2
6878196 Harada et al. Apr 2005 B2
6916927 Bunnage et al. Jul 2005 B2
6965032 Freudenberger et al. Nov 2005 B2
7192906 Hirohara et al. Mar 2007 B2
7196104 Askew, Jr. et al. Mar 2007 B2
7319108 Schwink et al. Jan 2008 B2
7774978 Ding et al. Aug 2010 B2
7803832 Critcher et al. Sep 2010 B2
7910606 Nazare et al. Mar 2011 B2
7923573 Tamaki et al. Apr 2011 B2
8163756 Flynn et al. Apr 2012 B2
8222280 Liu et al. Jul 2012 B2
8901153 Buysse et al. Dec 2014 B2
9029556 Yang et al. May 2015 B1
20020013326 Tiebes et al. Jan 2002 A1
20030153464 Nakamura et al. Aug 2003 A1
20030213405 Harada et al. Nov 2003 A1
20040043904 Yamaguchi et al. Mar 2004 A1
20040082629 Iwataki et al. Apr 2004 A1
20050038059 Mueller et al. Feb 2005 A1
20050176710 Schwink et al. Aug 2005 A1
20060135778 Schnatterer et al. Jun 2006 A1
20060160857 Buettelmann et al. Jul 2006 A1
20060160875 Gaines et al. Jul 2006 A1
20060167020 Dickerson et al. Jul 2006 A1
20060287365 Billen et al. Dec 2006 A1
20060287541 Nishino et al. Dec 2006 A1
20070049604 Nam et al. Mar 2007 A1
20070167426 Siddiqui et al. Jul 2007 A1
20080004301 Tamaki et al. Jan 2008 A1
20080027046 Annan et al. Jan 2008 A1
20090023709 Gillespie et al. Jan 2009 A1
20090069288 Breinlinger et al. Mar 2009 A1
20090137524 Billen et al. May 2009 A1
20090325956 Taniguchi et al. Dec 2009 A1
20100130474 Bothmann et al. May 2010 A1
20100204164 Crouse et al. Aug 2010 A1
20100286169 Guiles et al. Nov 2010 A1
20100292253 Trullinger et al. Nov 2010 A1
20100305200 Velicelebi et al. Dec 2010 A1
20110021771 Mallais et al. Jan 2011 A1
20110048261 Shimura Mar 2011 A1
20110098287 Bretschneider et al. Apr 2011 A1
20110118290 Bretschneider et al. May 2011 A1
20110166129 Machacek et al. Jul 2011 A1
20110166143 Bretschneider et al. Jul 2011 A1
20110184188 Wada et al. Jul 2011 A1
20110201649 Matsuzaki et al. Aug 2011 A1
20110212949 Bretschneider et al. Sep 2011 A1
20110275583 Bretschneider et al. Nov 2011 A1
20110319428 Fublein et al. Dec 2011 A1
20120053146 Parker et al. Mar 2012 A1
20120094837 Muhlthau et al. Apr 2012 A1
20120095023 Bretschneider et al. Apr 2012 A1
20120110701 Garizi et al. May 2012 A1
20120110702 Yap et al. May 2012 A1
20120115811 Du et al. May 2012 A1
20120165345 Bretschneider et al. Jun 2012 A1
20120172218 Crouse et al. Jul 2012 A1
20120220453 Lowe et al. Aug 2012 A1
20120252770 Berger et al. Oct 2012 A1
20130072382 Trullinger et al. Mar 2013 A1
20130089622 Trullinger et al. Apr 2013 A1
20130109566 Niyaz et al. May 2013 A1
20130261141 Bretschneider et al. Oct 2013 A1
20130288893 Buysse et al. Oct 2013 A1
20130291227 Buysse et al. Oct 2013 A1
20130324736 Ross, Jr. et al. Dec 2013 A1
20130324737 Ross, Jr. et al. Dec 2013 A1
Foreign Referenced Citations (83)
Number Date Country
0097323 Jan 1984 EP
0190457 Aug 1986 EP
0205024 Dec 1986 EP
0248315 Dec 1987 EP
0425948 May 1991 EP
1273582 Jan 2003 EP
1321463 Jun 2003 EP
1329160 Jul 2003 EP
1987-153273 Jul 1987 JP
1988-174905 Jul 1988 JP
1989-226815 Sep 1989 JP
2003-212864 Jul 2003 JP
2004-051628 Feb 2004 JP
2004-292703 Oct 2004 JP
2012-188418 Oct 2012 JP
2013-075871 Apr 2013 JP
2013-082699 May 2013 JP
2013-082704 May 2013 JP
2013-107867 Jun 2013 JP
2013-129651 Jul 2013 JP
2013-129653 Jul 2013 JP
9413644 Jun 1994 WO
9736897 Oct 1997 WO
9849166 Nov 1998 WO
0035919 Jun 2000 WO
0134127 May 2001 WO
0190078 Nov 2001 WO
02083111 Oct 2002 WO
03008405 Jan 2003 WO
03072102 Sep 2003 WO
2004041813 May 2004 WO
2005070925 Aug 2005 WO
2005074875 Aug 2005 WO
2006023462 Mar 2006 WO
2006033005 Mar 2006 WO
2006046593 May 2006 WO
2006103045 Oct 2006 WO
2007005838 Jan 2007 WO
2007087427 Aug 2007 WO
2007098826 Sep 2007 WO
2008005457 Jan 2008 WO
2008079277 Jul 2008 WO
2008090382 Jul 2008 WO
2009149858 Dec 2009 WO
2010006713 Jan 2010 WO
2010009290 Jan 2010 WO
2010012442 Feb 2010 WO
2010033360 Mar 2010 WO
2010048207 Apr 2010 WO
2010060379 Jun 2010 WO
2010075376 Jul 2010 WO
2010129497 Nov 2010 WO
2010133336 Nov 2010 WO
2010146236 Dec 2010 WO
2011003065 Jan 2011 WO
2011043371 Apr 2011 WO
2011045224 Apr 2011 WO
2011045240 Apr 2011 WO
2011091153 Jul 2011 WO
2011101229 Aug 2011 WO
2011126903 Oct 2011 WO
2011128304 Oct 2011 WO
2011134964 Nov 2011 WO
2011138285 Nov 2011 WO
2011163518 Dec 2011 WO
2012000896 Jan 2012 WO
2012004217 Jan 2012 WO
2012007500 Jan 2012 WO
2012035011 Mar 2012 WO
2012052412 Apr 2012 WO
2012061290 May 2012 WO
2012070114 May 2012 WO
2012102387 Aug 2012 WO
2012108511 Aug 2012 WO
2012147107 Nov 2012 WO
2012168361 Dec 2012 WO
2013000931 Jan 2013 WO
2013010946 Jan 2013 WO
2013010947 Jan 2013 WO
2013062980 May 2013 WO
2013064324 May 2013 WO
2013156431 Oct 2013 WO
2013156433 Oct 2013 WO
Non-Patent Literature Citations (18)
Entry
Kempe et al., “Responsive Glyco-poly(2-oxaoline)s: Synthesis, Cloud Point Tuning, and Lectin Binding,” Biomacromolecules 2011, vol. 12, pp. 2591-2600.
Fields et al., “Preparation of Trifluoromethyl-Pyrazoles and -Pyrazolines by the Reaction of 2,2,2-Trifluorodiazoethane with Carbon-Carbon Multiple Bonds,” Journal of Fluorine Chemistry, 1979, vol. 13, pp. 147-158.
Bradbury et al., “Enzyme-catalysed peptide amidation,” Eur. J. Biochem. 1987, vol. 169, pp. 579-584.
International Search Report and Written Opinion for PCT/US2014/061005 mailed Dec. 16, 2014.
International Search Report and Written Opinion for PCT/US2014/061006 mailed Dec. 8, 2014.
International Search Report and Written Opinion for PCT/US2014/061007 mailed Dec. 31, 2014.
International Search Report and Written Opinion for PCT/US2014/061009 mailed Dec. 8, 2014.
International Search Report and Written Opinion for PCT/US2014/061010 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061012 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061014 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061016 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061022 mailed Dec. 29, 2014.
International Search Report and Written Opinion for PCT/US2014/061023 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061024 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061027 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061029 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2014/061030 mailed Dec. 15, 2014.
International Search Report and Written Opinion for PCT/US2013/029615 mailed May 8, 2013.
Related Publications (1)
Number Date Country
20160031849 A1 Feb 2016 US
Provisional Applications (1)
Number Date Country
62031557 Jul 2014 US
Continuations (1)
Number Date Country
Parent 14517357 Oct 2014 US
Child 14666822 US